About Abryl Formulations Private Limited
Data last updated:
Abryl Formulations Private Limited is a foreign private limited company based in Bathinda, Punjab, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 23 August 2006 and has been in existence for over 20 years.
The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN U24239PB2006FTC030567. Its GSTIN is 03AAFCA8593C2ZS (Punjab). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹9 Lakh and a paid-up capital of ₹9 Lakh. It is led by directors Aditya Singla and Sanjeev Agnihotri.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 17406A Street No. 3 Minocha Colony, Bathinda, Punjab, India – 151001.
As per the financials filed for FY 2025, the company reported a revenue of ₹87.19 Lakh, a growth of 55% compared to the previous year. For the same year it recorded a net profit of ₹10.55 Lakh (net margin 12.1%) and EBITDA of ₹14.11 Lakh (EBITDA margin 16.2%). Revenue has grown at a compounded annual rate (CAGR) of 19% over three years and 9% over five years.
The company has 3 deals on record (2 secondary share transfers, 1 funding round), with disclosed funding of ₹8 Lakh; the latest was in January 2015. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Hadwin Pharma Private Limited.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website abryl.in.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered Address17406A Street No. 3 Minocha Colony, Bathinda, Punjab, India – 151001
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Abryl Formulations Private Limited
The main business activity of Abryl Formulations is professional, scientific and technical. In detail, this covers other professional, scientific and technical activities.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M9 | Other professional, scientific and technical activities | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Abryl Formulations Private Limited FY 2025 filings available
Abryl Formulations Private Limited reported revenue of ₹87.19 Lakh (up 55% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Abryl Formulations Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 9% over five years, including 55% growth in the latest year. EBITDA rose 252% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Abryl Formulations Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹14.11 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹10.55 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Abryl Formulations Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 16.2% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 12.1% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Abryl Formulations are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Abryl Formulations Private Limited
Abryl Formulations Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Revenue, net profit, margin and growth of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Hadwin Pharma Private Limited | •••• | •••• | •••• | •••• | - | Hyderabad, Telangana, India |
| Pharmastra Lifecare Private Limited | •••• | •••• | •••• | •••• | - | Sanand, Gujarat, India |
| Kupvit Healthcare Private Limited | •••• | •••• | •••• | •••• | - | Aurangabad, Maharashtra, India |
| Dawawale Pharmaceuticals Limited | •••• | •••• | •••• | •••• | - | Noida, Uttar Pradesh, India |
| Stenora Pharma Private Limited | •••• | •••• | •••• | •••• | - | Mumbai, Maharashtra, India |
| Abryl Formulations Private Limited this company | •••• | •••• | •••• | •••• | - | Bathinda, Punjab, India |
| Winmark Healthcare Private Limited | •••• | •••• | •••• | •••• | - | Mumbai, Maharashtra, India |
| Doux Healthcare Private Limited | •••• | •••• | •••• | •••• | - | Panchkula, Haryana, India |
| Nikol Health Care Private Limited | •••• | •••• | •••• | •••• | - | Talod, Gujarat, India |
| V-Revive Medicure Private Limited | •••• | •••• | •••• | •••• | - | Chandigarh, India |
| Preet Pharma Pvt Ltd | •••• | •••• | •••• | •••• | - | Ahmedabad, Gujarat, India |
Peers are the five companies nearest above and the five nearest below Abryl Formulations by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Revenue, net profit, margin and growth of each peer are in the company report.
Auditor Details of Abryl Formulations Private Limited
Abryl Formulations Private Limited is audited by PRIYA BHUSHAN SHARMA & CO. for the financial year 2024.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| PRIYA BHUSHAN SHARMA & CO. | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Abryl Formulations Private Limited
Abryl Formulations has 2 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Aditya Singla | Director | 20 Aug 2024 | 2 Years 1 Months | Current |
| Sanjeev Agnihotri | Director | 11 Oct 2025 | 0 Years 11 Months | Current |
Ownership and Shareholding of Abryl Formulations Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Abryl Formulations Private Limited
Abryl Formulations Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Deals & Funding of Abryl Formulations Private Limited
Abryl Formulations Private Limited has 3 deals on record (2 secondary share transfers, 1 funding round), with disclosed funding of ₹8 Lakh; the latest was in January 2015.
Deals on record (3 of 3)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jan 2015 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| May 2010 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Jan 2010 | Funding round | ₹8 Lakh | Investors: 3 individuals |
Full deal history
All 3 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Employees and EPFO Compliance at Abryl Formulations Private Limited
Employment history and EPFO contributions of people linked to Abryl Formulations.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
CIN History of Abryl Formulations Private Limited
Abryl Formulations has one previous CIN (Corporate Identification Number): L24239PB2006FTC030567. The current CIN is U24239PB2006FTC030567, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239PB2006FTC030567 | Current |
| L24239PB2006FTC030567 | Previous |
Recent Activity on Abryl Formulations Private Limited
Abryl Formulations Private Limited has 6 board changes on record since 2010: 2 appointments and 4 cessations. The latest: Neerja Singla ceased to be Director on 10 Dec 2025.
Credit Ratings, Litigation & Regulatory Alerts for Abryl Formulations Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Abryl Formulations Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Abryl Formulations Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Abryl Formulations Private Limited
Abryl Formulations has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 03AAFCA8593C2ZS | Punjab | Active | 08 Nov 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Abryl Formulations Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abryl Formulations Private Limited
Abryl Formulations is an active foreign private limited company based in Bathinda, Punjab, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 23 August 2006 (20+ years old) and is registered under CIN U24239PB2006FTC030567.
Abryl Formulations reported revenue of ₹87.19 Lakh for FY 2025 (up 55% YoY).
Abryl Formulations has 2 current directors:
- Aditya Singla - Director
- Sanjeev Agnihotri - Director
Abryl Formulations reported a net profit of ₹10.55 Lakh (net margin 12.1%) and EBITDA of ₹14.11 Lakh (EBITDA margin 16.2%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Abryl Formulations is 19% over three years and 9% over five years. In the latest year (FY 2025) revenue rose 55%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Abryl Formulations is 03AAFCA8593C2ZS, registered in Punjab. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Abryl Formulations is U24239PB2006FTC030567. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Abryl Formulations was incorporated on 23 August 2006, making it 20+ years old. It is registered with the Registrar of Companies, Chandigarh.
Abryl Formulations has 3 deals on record (2 secondary share transfers, 1 funding round), with disclosed funding of ₹8 Lakh; the latest was in January 2015.
The peers of Abryl Formulations by revenue are Hadwin Pharma Private Limited, Pharmastra Lifecare Private Limited, Kupvit Healthcare Private Limited, Dawawale Pharmaceuticals Limited, Stenora Pharma Private Limited and 5 more, all in the Pharma industry (Formulations).
Neerja Singla ceased to be Director on 10 Dec 2025. Sanjeev Agnihotri was appointed as Director on 11 Oct 2025. Aditya Singla was appointed as Director on 20 Aug 2024. Abryl Formulations has 6 board changes on record in total.